Abbott Laboratories Corporation

Other

James F Kerwin

William A Carroll

Robert J Altenbach

Irene I Drizin

Michael D Meyer

Fatima Z Basha

Michael D Wendt

Kevin B Sippy

Karin Rosemarie Tietje

Suzanne A Lebold

Edmund L Lee

Marlon D Cowart

Mark W Holladay

Alex M Nadzan

Diane M Yamamoto

Chun W Lin

Ferid Murad

Lee D Gorsky

John K Pratt

Anthony Ralph Haight

Teodozyj Kolasa

Jeffrey J Rohde

Jimmie L Moore

Weijiang Zhang

Michael J Bennett

Yiyuan Chen

Albert Khilevich

Steven W Elmore

Teresa McNally

Donald N Halbert

Cyclopentanone dihydropyridine compounds useful as potassium channel openers

Imidazoles and related compounds as &agr;1A agonists

The present invention relates to a compound of the formula and the pharmaceutically acceptable salts thereof wherein W is a bicyclic heterocyclic ring system. The compounds are .alpha.-1 adrenergic antagonists and are useful in the treatment of BPH; also disclosed are .alpha.-1 antagonist compositions and a method for antagonizing .alpha.-1 adrenoreceptors and treating BPH.

Benzopyranopyrrole and benzopyranopyridine .alpha.-1 adrenergic compounds

The present invention relates to a compound of the formula ##STR1## and the pharmaceutically acceptable salts thereof wherein W is a bicyclic heterocyclic ring system. The compounds are .alpha.-1 adrenergic antagonists and are useful in the treatment of BPH; also disclosed are .alpha.-1 antagonist compositions and a method for antagonizing .alpha.-1 adrenoreceptors and tr

Benzopyranopyrrole and benzopyranopyridine .alpha.-1 adenergic compounds

The present invention provides an adenosine kinase protein having an identified structural formula. The identified protein or similar adenosine kinase proteins having residues as claimed and recited herein may be isolated and purified from natural sources or produced by recombinant DNA technology.

Adenosine kinase polypeptides

The present invention relates to a compound of the formula ##STR1## and the pharmaceutically acceptable salts thereof wherein W is a bicyclic heterocyclic ring system. The compounds are .alpha.-1 adrenergic antagonists and are useful in the treatment of BPH; also disclosed are .alpha.-1 antagonist compositions and a method for antagonizing .alpha.-1 receptors and treating BPH.

Bicyclic substituted hexahydrobenz �e! isoindole alpha-1 adrenergic

The present invention relates to a compound of the formula ##STR1## and the pharmaceutically acceptable salts thereof wherein W is a tricyclic heterocyclic ring system; which is an .alpha.-1 adrenergic antagonist and is useful in the treatment of BPH; also disclosed are .alpha.-1 antagonist compositions and a method for antagonizing .alpha.-1 receptors and treating BPH.

Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic

Bicyclic substituted hexahydrobenz[e]isoindole .alpha.-1 adrenergic

Compounds of the formula: ##STR1## useful as regulators of nitric oxide synthase that indirectly modulate cyclic guanosine monophosphate (cGMP), pharmaceutical compositions thereof, for treating disorders of vascular smooth muscles, macrophages, neurons, platelets, bronchial smooth muscles, optic muscles and gastrointestinal smooth muscles, sickle cell anemia and diabetes.

Guanidino compounds as regulators of nitric oxide synthase

2-Nitroaryl or 2-cyanoaryl compounds of the formula ##STR1## pharmaceutical compositions thereof, intermediates useful in the preparation of these compounds, and methods for treating disorders of vascular smooth muscles or diseases of the cartilage, macrophages, neurons, platelets, bronchial smooth muscles, optic muscles and gastrointestinal smooth muscles, in addition to sickle cell anemia, diabetes, synovitis, chondroarthritis and osteoarthritis by employing these compounds.

2-nitroaryl and 2-cyanoaryl compounds as regulators of nitric oxide

Analogs of CCK-tetrapeptides, which analogs have the formula ##STR1## wherein A, B, D, R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are specifically defined, having activity as CCK antagonists, useful in the treatment or prevention of disorders of the gastrointestinal, central nervous, appetite regulating or pain regulating systems.

Amino acid analog CCK antagonists

A compound of the formula: ##STR1## wherein R.sub.1 and R.sub.2 are substituents; R.sub.6 is hydrogen, loweralkyl, cycloalkyl, loweralkenyl, arylalkyl, (substituted aryl)alkyl, or (heterocyclic)alkyl; B is a bond, an alkylene group, an alkenylene group, an alkadienylene group or a heteroatom containing linking group; D is a substituted acyl group or tetrazolyl; Z is CO, C(S) or S(O).sub.2 ; Ar is a heterocyclic group; and n is 1 to 3. Also disclosed are a composition and a method for antagonizing CCK, a composition and method for treating or preventing gastrointestinal, central nervous, appetite regulating and pain regulating systems, a composition and method for treating or preventing hyperinsulinemia, methods of making the compounds and intermediates useful in making the compounds.

Derivatives of D-glutamic acid and D-aspartic acid

Growing community of inventors

Grayslake, IL, United States of America

James F Kerwin